Jeong Youn Lim

Jeong Youn Lim

Auto-generated profile, based on publicly available information

Jeong Youn Lim

Biostatistics Shared Resource Knight Cancer Institute Oregon Health and Science University Portland Oregon USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2024 in Future Oncology
Verified
Journal Article
Closed access
CLCharles D Lopez
Charles D Lopez
AKAdel Kardosh
Adel Kardosh
ECEmerson Y. Chen
Emerson Y. Chen
GPGuillaume Pegna
Guillaume Pegna
AGAlexander Guimaraes
Alexander Guimaraes
RSRosalie C. Sears
Rosalie C. Sears
Asparagine synthetase (ASNS) catalyzes the biosynthesis of asparagine from aspartate and glutamine. Cells lacking ASNS, however, are auxotrophic for asparagine. Use of L-asparaginase to promote asparagine starvation in solid tumors with low ASNS levels, such as pancreatic ductal adenocarcinoma (PDAC), is a rationale treatment strategy. However, tumor cell resistance to L-asparaginase has limited its clinical utility. Our preclinical studies show that RAS/MAPK signaling circumvents L-asparaginase-induced tumor killing, but L-asparaginase and MEK inhibition potentiated tumor killing; suggesting that this combination may provide meaningful clinical benefit to patients with PDAC. This Phase I trial (NCT05034627) will evaluate the safety and tolerability of the MEK inhibitor, cobimetinib, in combination with pegylated L-asparaginase, L calaspargase pegol-mknl, in patients with locally-advanced or metastatic PDAC.

30 August 2024 in medRxiv
Verified
Preprint
Open access
PDF file
ZMZahi I. Mitri
Zahi I. Mitri
ACAllison L. Creason
Allison L. Creason
JSJayne Stommel
Jayne Stommel
TOTugba Y. Ozmen
Tugba Y. Ozmen
MRMatthew J. Rames
Matthew J. Rames
SPSmmart Clinical Trials Program
Smmart Clinical Trials Program
In syngeneic murine breast cancer models, poly(ADP-ribose) polymerase inhibitor (PARPi) and anti-PD-L1 combinations induce deep, sustained responses independent of BRCA1 or BRCA2 mutation (BRCAm) status. We therefore investigated this combination in the AMTEC clinical trial, in which a one-month olaparib run-in was followed by combined olaparib and durvalumab in participants with non-BRCAm metastatic triple negative breast cancer. To characterize adaptive responses to olaparib monotherapy, paired biopsies taken before and during the PARPi lead-in were deeply characterized by DNA, RNA, and protein multi-omic analyses, including spatially resolved single-cell proteomics for tumor and immune contexture. We identified multiple potential tumor-intrinsic and microenvironmental biomarkers from pre-treatment and on-olaparib biopsies that robustly predicted participant response to combined olaparib and durvalumab. Notably, the on-olaparib biopsy provided the greatest information content, suggesting that early adaptations of malignant and immune cells to PARPi can serve as a predictor of potential benefit from combined PARPi and anti-PD-L1 therapy.

30 July 2024 in Electrophoresis
Verified
Journal Article
Open access
JWJason P Ware
Jason P Ware
DSDelaney Shea
Delaney Shea
JLJeong Youn Lim
Jeong Youn Lim
AMAnna Malakian
Anna Malakian
RARandall Armstrong
Randall Armstrong
SIStuart D. Ibsen
Stuart D. Ibsen
Dielectrophoresis (DEP) is a fast and reliable nanoparticle recovery method that utilizes nonuniform electric fields to manipulate particles based on their material composition and size, enabling recovery of biologically‐derived nanoparticles from plasma for diagnostic applications. When applying DEP to undiluted human plasma, collection of endogenous albumin proteins was observed at electric field gradients much lower than predicted by theory to collect molecular proteins. To understand this collection, nanoparticle tracking analysis of bovine serum albumin (BSA) dissolved in 0.5× phosphate‐buffered saline was performed and showed that albumin spontaneously formed aggregate nanoparticles with a mean diameter of 237 nm. These aggregates experienced a dielectrophoretic force as a function of aggregate radius rather than the diameter of individual protein molecules which contributed to their collection. In high conductance buffer (6.8 mS/cm), DEP was able to move these aggregates into regions of high electric field gradient, and in lower conductance buffer (0.68 mS/cm), these aggregates could be moved into high or low gradient regions depending on the applied frequency. Disruption of BSA aggregates using a nonionic detergent significantly decreased the particle diameter, resulting in decreased dielectrophoretic collection of albumin which increased the collection consistency of particles of interest. These results provide techniques to manipulate albumin aggregates via DEP, which impacts collection of diagnostic biomarkers.

8 April 2026 in Small
Verified
Journal Article
Open access
AMAnna Malakian
Anna Malakian
AMAugusta Modestino
Augusta Modestino
JBJesus Bueno
Jesus Bueno
AMArchana Machireddy
Archana Machireddy
JWJason P Ware
Jason P Ware
SIStuart D. Ibsen
Stuart D. Ibsen
Cancer‐derived extracellular vesicle (EV) nanoparticles carry important biomarkers but are difficult to recover from plasma, making EV‐based diagnostics a challenge for clinical settings. Here, we demonstrate nanoparticle‐based detection of pancreatic cancer using dielectrophoresis (DEP) nanoparticle recovery technology, which purifies nanoparticles from undiluted plasma and quantifies associated biomarkers. We combined both nanoparticle recovery and biomarker quantification on a single device by simultaneously collecting cell‐free DNA nanoparticles and EVs followed by on‐chip biomarker fluorescent staining for DNA and Glypican‐1. Using a blinded cohort, these biomarkers differentiated pancreatic cancer from benign pancreatic diseases, including cysts, pancreatitis, and precancerous low‐grade intraductal papillary mucinous neoplasm (IPMN) lesions, with a sensitivity of 0.92, a specificity of 0.83, and an AUC of 0.93. The AUC increased to 0.97 for patients over 50 years old. This is higher than the standard invasive endoscopic ultrasound‐guided fine needle aspiration tissue biopsy procedure (AUC 0.79). This study is among the first demonstrating a combined threshold of DNA and protein levels that can distinguish pancreatic cancer from its precursor IPMN lesions. We also demonstrated the detection of early‐stage pancreatic cancer and high‐grade in situ precancerous lesions. This DEP‐based technique shows that multiple types of cancer‐derived nanoparticles can be quickly and easily recovered from plasma making it promising for future clinical diagnostics.

23 October 2026 in Head & Neck
Verified
Journal Article
Closed access
CCCameron Chalker
Cameron Chalker
JBJason C. Burton
Jason C. Burton
AKAndy Kaempf
Andy Kaempf
JLJeong Youn Lim
Jeong Youn Lim
SLSarah Lowry
Sarah Lowry
EREric J. Roeland
Eric J. Roeland